[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"demodex-blepharitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:demodex-blepharitis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100636112","phase-4-demodex-blepharitis-in-scleral-lens-wearers-100636112",false,"NCT07561450","Demodex Blepharitis in Scleral Lens Wearers","Inclusion Criteria:.\n\n1. Written Informed Consent has been obtained prior to any study-related procedures taking place\n2. Subject is Male or Female, 18 years of age or older prior to the initial visit\n3. Is an established wearer of PROSE devices for \\> 6 months in both eyes\n4. Currently wears PROSE devices on a daily basis in both eyes\n5. No plans to alter the PROSE lens design in either eye during the study period\n6. Bilateral Demodex Blepharitis (\\> Grade 2, which is more than 10 upper lash collarettes, worse eye)\n7. Baseline CLDEQ-8 score of 12 or higher\n8. Baseline VAS score of 40 or above for frequency OR severity in ONE of the following:\n\ntolerability, blurred vision, ocular burning, ocular redness or ocular itching 9. In the opinion of the investigator, the subject can follow study instructions 10. In the opinion of the investigator, the subject can complete all study procedures and visits\n\n\\-\n\nExclusion Criteria:\n\n1. Is currently participating in any other type of eye-related clinical research study\n2. Is pregnant or nursing as reported by the subject.\n3. Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study.\n4. Has had previous ocular surgery within the past 12 weeks or has planned ocular surgery during the study period.\n5. Has initiated any new blepharitis or ocular surface treatment within the last 12 weeks\n6. The subject is only wearing a PROSE device in one eye.\n7. The participant is monocular\n8. The participant carries a diagnosis of glaucoma or ocular hypertension or glaucoma suspect AND is currently using glaucoma medications\n9. Allergy to sodium fluorescein\n10. Allergy to XDEMVY (lotilaner ophthalmic solution) 0.25%\n\n    \\-","ALL","18 Years",{"count":18,"type":19},5,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The purpose of this study will be to see if Xdemvy (lotilaner ophthalmic solution) 0.25% has a positive impact on ocular surface symptoms and PROSE device functionality and performance.\n\nThe investigators hypothesize the use of Xdemvy in subjects utilizing PROSE treatment will be well tolerated and that the reduction in Demodex mite load on the eyelid margin will result in reduced ocular surface symptoms and improved PROSE tolerance and functionality.",[25],"Demodex Blepharitis",[27],"Blepharitis","NOT_YET_RECRUITING","2026-04-28",{"date":31,"type":32},"2026-05-01","ACTUAL",{"date":34,"type":19},"2026-04-27",{"date":36,"type":19},"2027-02",{"name":38,"class":39},"Boston Sight","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100623771","phase-2-evaluation-of-the-safety-and-efficacy-of-glk-321-in-subjects-with-demodex-blepharitis-100623771","NCT07400965","Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis","Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis","Inclusion Criteria:\n\n* Signs of Demodex blepharitis in at least one eye\n* Best Spectacle Corrected Visual Acuity (BSCVA) of 20\u002F80 Snellen or better in each eye\n\nExclusion Criteria:\n\n* Presence of eczema or dermatitis in the ocular region of either eye\n* Use of lid hygiene products within 14 days of Screening\n* Active ocular infection or inflammation, other than blepharitis, in either eye at Screening\n* Women who are pregnant, planning a pregnancy, or nursing\n* Have used an investigational drug or device within 30 days prior to Screening or concurrently enrolled in another investigational drug or device trial",{"count":48,"type":19},250,[50],"PHASE2","This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.",[25],[54],"demodex blepharitis","RECRUITING","2026-02-24",{"date":58,"type":32},"2026-02-27",{"date":60,"type":32},"2025-12-05",{"date":62,"type":19},"2026-11",{"name":64,"class":65},"Glaukos Corporation","INDUSTRY",1]